Key Highlights
- Jeltje Schulten, M.D., MBA, joins as SVP of Clinical and Medical Affairs with over 25 years of experience in oncology drug development.
- Rita Dalal, MBBS, MPH, appointed as VP of Clinical Development, brings extensive clinical research experience in solid tumor oncology.
- The appointments are set to advance BCA101, a first-in-class bifunctional antibody, for the treatment of various solid tumors including HPV-negative head and neck cancer.
Source: Business Wire
Notable Quote
- “We are very pleased to welcome Jeltje and Rita to our talented team. They each bring significant oncology drug development expertise… and we are confident that their collective skillset will help us to further accelerate and expand the BCA101 program to reach patients in need,” – Claire Mazumdar, Ph.D., MBA, Chief Executive Officer at Bicara Therapeutics
SoHC's Take
Bicara Therapeutics’ recent appointments of Dr. Jeltje Schulten and Dr. Rita Dalal mark a strategic enhancement to their clinical and medical affairs team. These additions reflect the company’s commitment to advancing its pioneering BCA101 program, which targets a dual-action mechanism against tumor growth and immune evasion. The extensive experience both executives bring from their tenure in oncology drug development is poised to significantly benefit Bicara Therapeutics’ mission to develop innovative cancer therapies. The ongoing development of BCA101, especially in the challenging field of solid tumors, showcases the potential of combining tumor-targeting antibodies with microenvironment modulators. This approach could redefine therapeutic strategies in oncology, promising a new horizon for patients grappling with complex cancer diagnoses.
